| Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV JE Gallant, E DeJesus, JR Arribas, AL Pozniak, B Gazzard, RE Campo, ... New England Journal of Medicine 354 (3), 251-260, 2006 | 1215 | 2006 |
| Lopinavir–ritonavir versus nelfinavir for the initial treatment of HIV infection S Walmsley, B Bernstein, M King, J Arribas, G Beall, P Ruane, M Johnson, ... New England Journal of Medicine 346 (26), 2039-2046, 2002 | 862 | 2002 |
| Evaluation of convalescent plasma for Ebola virus disease in Guinea J Van Griensven, T Edwards, X de Lamballerie, MG Semple, P Gallian, ... New England Journal of Medicine 374 (1), 33-42, 2016 | 650 | 2016 |
| Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study HJ Stellbrink, C Orkin, JR Arribas, J Compston, J Gerstoft, ... Clinical Infectious Diseases 51 (8), 963-972, 2010 | 483 | 2010 |
| Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial AM Borobia, AJ Carcas, M Pérez-Olmeda, L Castaño, MJ Bertran, ... The Lancet 398 (10295), 121-130, 2021 | 426 | 2021 |
| Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study A Castagna, F Maggiolo, G Penco, D Wright, A Mills, R Grossberg, ... The Journal of infectious diseases 210 (3), 354-362, 2014 | 420 | 2014 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 406 | 2019 |
| Clinical management of Ebola virus disease in the United States and Europe TM Uyeki, AK Mehta, RT Davey Jr, AM Liddell, T Wolf, P Vetter, ... New England Journal of Medicine 374 (7), 636-646, 2016 | 392 | 2016 |
| Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study J Del Amo, R Polo, S Moreno, A Díaz, E Martínez, JR Arribas, I Jarrín, ... Annals of internal medicine 173 (7), 536-541, 2020 | 389 | 2020 |
| Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised … J van Lunzen, F Maggiolo, JR Arribas, A Rakhmanova, P Yeni, B Young, ... The Lancet infectious diseases 12 (2), 111-118, 2012 | 374 | 2012 |
| Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active … A Mills, JR Arribas, J Andrade-Villanueva, G DiPerri, J Van Lunzen, ... The Lancet Infectious Diseases 16 (1), 43-52, 2016 | 368 | 2016 |
| Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain J Berenguer, P Ryan, J Rodriguez-Bano, I Jarrín, J Carratala, J Pachón, ... Clinical Microbiology and Infection 26 (11), 1525-1536, 2020 | 360 | 2020 |
| Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis JR Arribas, AL Pozniak, JE Gallant, E DeJesus, B Gazzard, RE Campo, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 47 (1), 74-78, 2008 | 335 | 2008 |
| A cohort of patients with COVID-19 in a major teaching hospital in Europe AM Borobia, AJ Carcas, F Arnalich, R Álvarez-Sala, J Monserrat-Villatoro, ... Journal of clinical medicine 9 (6), 1733, 2020 | 333 | 2020 |
| Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and … AL Pozniak, JE Gallant, E DeJesus, JR Arribas, B Gazzard, RE Campo, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 43 (5), 535-540, 2006 | 313 | 2006 |
| Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial AR Lifson, J Neuhaus, JR Arribas, M van den Berg-Wolf, AM Labriola, ... American journal of public health 100 (10), 1896-1903, 2010 | 311 | 2010 |
| Cytomegalovirus encephalitis JR Arribas, GA Storch, DB Clifford, AC Tselis Annals of internal medicine 125 (7), 577-587, 1996 | 302 | 1996 |
| Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients M Pérez-Olmeda, M Núñez, M Romero, J González, A Castro, JR Arribas, ... Aids 17 (7), 1023-1028, 2003 | 277 | 2003 |
| Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi, P Wung, N Patel, ... The Lancet Respiratory Medicine 9 (5), 522-532, 2021 | 261 | 2021 |
| Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications JR Rey, J Caro‐Codón, SO Rosillo, ÁM Iniesta, S Castrejón‐Castrejón, ... European journal of heart failure 22 (12), 2205-2215, 2020 | 252 | 2020 |
